Document Type
Article Presentation
Original Publication Date
2023
Date of Submission
June 2023
Abstract
This presentation focused on the inhibition of type 1 immunity with tofacitinib and its effect on patients with sarcoidosis. The drug tofacitinib is mainly a rheumatoid arthritis drug, and the main objective of the study was to see if the drug could be used for sarcoidosis. After the completion of the experiment, it was found that the drug dramatically reduced the CSAMI activity score (a score used to indicate the activity of sarcoidosis) by 82.7% on average after six months of use.
Rights
© The Author(s)
